These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
413 related items for PubMed ID: 15711261
1. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Project Team. J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261 [Abstract] [Full Text] [Related]
2. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team. J Natl Cancer Inst; 2005 Mar 16; 97(6):433-8. PubMed ID: 15770007 [Abstract] [Full Text] [Related]
7. [Screening of cancer of the prostate: study in a Spanish population]. Herrero Payo JA, Montes Díaz MJ, Páez Borda A, Sánchez Sánchez E, Moreno Valle JA, Berenguer Sánchez A. Arch Esp Urol; 1996 Apr 15; 49(6):595-606. PubMed ID: 8929102 [Abstract] [Full Text] [Related]
9. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. Eur Urol; 2008 Sep 15; 54(3):581-8. PubMed ID: 18423977 [Abstract] [Full Text] [Related]
11. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. J Urol; 2005 Aug 15; 174(2):489-94; discussion 493-4. PubMed ID: 16006878 [Abstract] [Full Text] [Related]
14. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL. Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL. BJU Int; 2012 Dec 15; 110(11 Pt B):E653-7. PubMed ID: 22892057 [Abstract] [Full Text] [Related]
18. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Schröder FH, Bangma CH, Roobol MJ. Eur Urol; 2008 May 15; 53(5):901-8. PubMed ID: 18262712 [Abstract] [Full Text] [Related]
19. Histological diagnosis of prostate cancer in Korean men aged 70-79 years. Shim HB, Lee SE, Park HK, Ku JH. Jpn J Clin Oncol; 2007 Oct 15; 37(10):782-7. PubMed ID: 17913831 [Abstract] [Full Text] [Related]
20. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, Chia D, Levin DL, Gohagan JK. Urology; 2006 Aug 15; 68(2):352-6. PubMed ID: 16904451 [Abstract] [Full Text] [Related] Page: [Next] [New Search]